Invited Speakers

Memorial Lecture

  • ML01 Translating DNA Repair for Targeting Cancers Prof. Kyungjae Myung UNIST / Institute for Basic Science, Korea CV
  • ML02 Biological Heterogeneity of AML: Implications for Prognosis and Treatment Prof. Clara Bloomfield The Ohio State University, USA CV
  • ML03 Approaching Survival of the General Population: The Results of CML Study IV in the Global Context Prof. Rüdiger Hehlmann Heidelberg University, Germany CV
  • ML04 New Models of Human Leukemia Dr. Connie Eaves British Columbia Cancer Agency, Canada CV
  • ML05 Integrating CAR T-Cell Therapy into the Treatment of Lymphoma, Myeloma, and Leukemia: Strategies for Maximizing Patient Outcomes Prof. David G. Maloney Fred Hutchinson Cancer Research Center, USA CV
  • ML06 Leukemia Stem Cell and Bone Marrow Microenvironment Interactions Prof. Ravi Bhatia The University of Alabama at Birmingham, USA CV
  • ML07 Understanding Evolution and Outcomes in Myeloproliferative Neoplasms Dr. Jyoti Nangalia Wellcome Sanger Institute, UK CV

Keynote Speech

  • KS Infectious Origins of Some Leukemias & What To Do Director Robert Gallo University of Maryland, USA CV

Session 01: Virus Associated Hematologic Malignancies

  • SY01-1 A Novel Epigenetic Drug against Adult T-cell Leukemia Prof. Toshiki Watanabe The University of Tokyo, Japan CV
  • SY01-2 TBD TBD TBD
  • SY01-3 Using HTLV-1/BLV Genomics to Understand Adult T-cell Leukemia Dr. Anne Van den Broeke Jules Bordet Institute - ULB, Belgium
  • SY01-4 Can We Cure Adult T Cell Leukemia/Lymphoma? Prof. Ali Bazarbachi American University of Beirut-Medical Center, Lebanon CV

Session 02: Myelodysplastic Syndromes

  • SY02-1 DNA Methylation and Hydroxymethylation in Hematologic Differentiation and Transformation Prof. Myunggon Ko Ulsan National Institute of Science and Technology, Korea CV
  • SY02-2 MDS - The Old and New Prof. Moshe Mittelman Tel Aviv Sourasky Medical Center, Israel CV
  • SY02-3 TBD TBD TBD
  • SY02-4 Hypomethylation-based Combination Treatments: Where Epigenetics Meets Immunotherapy Prof. Michael Lübbert University of Freiburg Medical Center, Germany CV

Session 03: Acute Myeloid Leukemia

  • SY03-1 The Rapidly Evolving Landscape in AML Prof. Gert Ossenkoppele Amsterdam University Medical Center, location VUMC, The Netherlands CV
  • SY03-2 Curative Treatment Options for Older Patients with AML Prof. Hervé Dombret Saint-Louis Institute for Research/ University of Paris, France CV
  • SY03-3 Development of A Novel FLT3 Inhibitor Prof. Hitoshi Kiyoi Nagoya University, Japan CV
  • SY03-4 Functional Genomic Approaches to Identifying New Therapeutic Strategies for AML Prof. Jeffrey Tyner Oregon Health & Science University, USA CV

Session 4: Chronic Myeloid Leukemia

  • SY04-1 Next Generation Sequencing for Chronic Myeloid Leukemia Prof. Susan Branford Centre for Cancer Biology, SA Pathology, Australia CV
  • SY04-2 New Horizon for CML Therapy: Treatment Discontinuation (TFR) Prof. Giuseppe Saglio University of Turin, Italy CV
  • SY04-3 French Experience of CML Management Prof. Françoise Guilhot France
  • SY04-4 Role of Allogeneic Stem Cell Transplantation in CML Prof. Jane Apperley Hammersmith Hospital, UK

Session 5: Multiple Myeloma

  • SY05-1 Clinical and Biological Significance of RNA Editing Defect in Myeloma Prof. Wee Joo Chng National University Health System, Singapore CV
  • SY05-2 NGS of MM Prof. Giovanni Martinelli IRST, Italy
  • SY05-3 TBD TBD TBD

Session 6: Acute Lymphoblastic Leukemia

  • SY06-1 Analysis of CNS-ALL with Patient Derived Xenografts (PDX) Model Prof. Itaru Kato Kyoto University, Japan CV
  • SY06-2 Targeting Cell Adhesion-mediated Resistance in ALL Prof. Yong-Mi Kim University of Southern California, USA CV
  • SY06-3 Minimal Residual Disease and Targeted Therapy in Acute Lymphoblastic Leukemia Prof. Dieter Hoelzer Onkologikum Frankfurt, Germany CV
  • SY06-4 Philadelphia Chromosome-Positive ALL : Evolving Place for TKIs, Chemotherapy, Targeted Therapy and Transplantation Dr. Françoise Huguet University Institute of Cancer, France CV

Session 7: Molecular Mechanisms

  • SY07-1 Understanding and Targeting the Stem Cell Origins of MDS and AML Prof. Ulrich Steidl Albert Einstein College of Medicine - Montefiore Medical Center, USA CV
  • SY07-2 Genetics and Mechanisms of Chemotherapy Resistance in ALL Prof. Adolfo Ferrando Columbia University, USA CV
  • SY07-3 Clonal Origin of Cancer Prof. Seishi Ogawa Kyoto University, Japan CV
  • SY07-4 Single-cell Sequencing for Understanding Tumor Heterogeneity and Evolution Prof. Semin Lee Ulsan National Institute of Science and Technology, Korea CV

Session 8: Lymphoma/ Chronic Lymphocytic Leukemia

  • SY08-1 Molecular Predictors and Prognosticators for the Clinical Management of Chronic Lymphocytic Leukemia Prof. Gianluca Gaidano University of Eastern Piedmont, Italy CV
  • SY08-2 Challenges Today in the Management of CLL Prof. Robin Foà ‘Sapienza’ University of Rome, Italy CV
  • SY08-3 Management of NK/T-cell Lymphoma Prof. Seok Jin Kim Samsung Medical Center, Korea CV
  • SY08-4 TBD Prof. John Seymour Peter MacCallum Cancer Center, Australia

Session 9: Myeloproliferative Neoplasms

  • SY09-1 2020 Classification and treatment options of JAK2 CALR and MPL mutated Myeloproliferative Neoplasms Prof. Jan Jacques Michiels Antwerp University Hospital, Belgium CV
  • SY09-2 TBD TBD TBD
  • SY09-3 TBD Prof. Hideki Muramatsu Nagoya University, Japan CV

Session 10: Leukemia Researches in Asian Sector

  • SY10-1 Study of Hematopoiesis Using Zebrafish Model System Dr. Yoonsung Lee UNIST / Institute for Basic Science, Korea CV
  • SY10-2 Nutrient Supply Specific to Chronic Myelogenous Leukemia Stem Cells Dr. Kazuhito Naka Hiroshima University, Japan CV
  • SY10-3 Overview of CAR-T Prof. Xiaojun Huang Peking University People's Hospital, China CV
  • SY10-4 TBD Prof. Jae Park Memorial Sloan Kettering Cancer Center, USA

Organized by